These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 10623426)
1. Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2. Gazitt Y; Shaughnessy P; Montgomery W Cytokine; 1999 Dec; 11(12):1010-9. PubMed ID: 10623426 [TBL] [Abstract][Full Text] [Related]
2. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Suliman A; Lam A; Datta R; Srivastava RK Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196 [TBL] [Abstract][Full Text] [Related]
3. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478 [TBL] [Abstract][Full Text] [Related]
4. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K; Douglas L; Delaney A; Houghton JA Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455 [TBL] [Abstract][Full Text] [Related]
5. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex. Izeradjene K; Douglas L; Delaney AB; Houghton JA Cancer Res; 2004 Nov; 64(21):8036-44. PubMed ID: 15520213 [TBL] [Abstract][Full Text] [Related]
6. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Sun SY; Yue P; Hong WK; Lotan R Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424 [TBL] [Abstract][Full Text] [Related]
7. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279 [TBL] [Abstract][Full Text] [Related]
8. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619 [TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Shipman CM; Croucher PI Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702 [TBL] [Abstract][Full Text] [Related]
10. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR; Shankar S; Chen X; Asim M; Srivastava RK Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373 [TBL] [Abstract][Full Text] [Related]
11. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related]
12. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154 [TBL] [Abstract][Full Text] [Related]
13. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339 [TBL] [Abstract][Full Text] [Related]
14. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Toomey NL; Deyev VV; Wood C; Boise LH; Scott D; Liu LH; Cabral L; Podack ER; Barber GN; Harrington WJ Oncogene; 2001 Oct; 20(48):7029-40. PubMed ID: 11704827 [TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Walczak H; Bouchon A; Stahl H; Krammer PH Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456 [TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Tang X; Sun YJ; Half E; Kuo MT; Sinicrope F Cancer Res; 2002 Sep; 62(17):4903-8. PubMed ID: 12208739 [TBL] [Abstract][Full Text] [Related]
17. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649 [TBL] [Abstract][Full Text] [Related]
18. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Knight MJ; Riffkin CD; Muscat AM; Ashley DM; Hawkins CJ Oncogene; 2001 Sep; 20(41):5789-98. PubMed ID: 11593384 [TBL] [Abstract][Full Text] [Related]
19. Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells. Oshima K; Yanase N; Ibukiyama C; Yamashina A; Kayagaki N; Yagita H; Mizuguchi J Cytokine; 2001 May; 14(4):193-201. PubMed ID: 11448118 [TBL] [Abstract][Full Text] [Related]
20. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]